The value of Business Enterprise R&D Expenditure in the Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations in the US is expected to see a steady increase from 2024 to 2028. In 2023, the actual expenditure stood at 122.03 billion US dollars PPP. Between 2024 and 2025, the expenditure is forecasted to grow by 6.9%, followed by an 6.43% increase from 2025 to 2026. This upward trend continues with a 5.97% growth from 2026 to 2027, and a 5.58% rise from 2027 to 2028. The Compound Annual Growth Rate (CAGR) over the forecast period from 2024 to 2028 is 6.28%, indicating consistent investment growth in the sector over these years.
Future trends to watch for include the impact of advancements in biotechnology, increased regulatory approvals for novel treatments, and the influence of emerging markets. Collaboration between pharmaceutical companies and technology firms can also drive innovation and efficiency in R&D activities.
